Date: Nov.24th	,2022	
Your Name:	Chunguang Li	

Manuscript Title: <u>Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic</u>

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time limit for this item.	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		X None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.24th	^h ,2022				
Your Name	Manling 7hu				

Manuscript Title: <u>Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic</u>

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.24th	,2022				
Your Name:	Oiiue Lu				

 $\textbf{Manuscript Title:} \underline{\quad Oncolytic \ adenovirus-mediated \ dual \ knockdown \ of \ survivin \ and \ OCT4 \ improves \ the rapeutic}$

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.24th	,2022				
Your Name:	Bovao Yu				

Manuscript Title: <u>Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic</u>

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time minit for this item.	Time frame: past	26 months
2	Grants or contracts from any entity (if not indicated	X_None	30 months
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		_X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Nov.24</u>	th ,2022				
Your Name: _	Yang Yang				

Manuscript Title: <u>Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic</u>

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time minit for this item.	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Nov.24</u>	th,2022			
Your Name:	Bin Li			

Manuscript Title: Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time minit for this item.	Time frame: past	26 months
2	Grants or contracts from any entity (if not indicated	X_None	30 months
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		_X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.24th	¹,2022			
V NI	71			

Your Name: Zhangxiao Peng

Manuscript Title: Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time minit for this item.	Time frame: past	26 months
2	Grants or contracts from	X None	30 months
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	
5		X None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.24th	1,2022				
Vour Name	7higang Li				

Manuscript Title: <u>Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic</u>

efficacy in esophageal cancer

Manuscript number (if known): ATM-22-4499-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
	No time mint for this item.	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	
5		_X_None	

	Payment or honoraria for	
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<u>X</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>X</u> None
8	Patents planned, issued or	<u>X</u> None
	pending	
9	Participation on a Data	<u>X</u> None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	<u>X</u> None
12	Receipt of equipment,	<u>X</u> None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	<u></u>

None

Please place an "X" next to the following statement to indicate your agreement: